154 related articles for article (PubMed ID: 38329392)
1. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry.
Sanz-Garcia E; Brown S; Lavery JA; Weiss J; Fuchs HE; Newcomb A; Postle A; Warner JL; LeNoue-Newton ML; Sweeney SM; Pillai S; Yu C; Nichols C; Mastrogiacomo B; Kundra R; Schultz N; Kehl KL; Riely GJ; Schrag D; Govindarajan A; Panageas KS; Bedard PL
Cancer Res Commun; 2024 Feb; 4(2):475-486. PubMed ID: 38329392
[TBL] [Abstract][Full Text] [Related]
2. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer.
Choudhury NJ; Lavery JA; Brown S; de Bruijn I; Jee J; Tran TN; Rizvi H; Arbour KC; Whiting K; Shen R; Hellmann M; Bedard PL; Yu C; Leighl N; LeNoue-Newton M; Micheel C; Warner JL; Ginsberg MS; Plodkowski A; Girshman J; Sawan P; Pillai S; Sweeney SM; Kehl KL; Panageas KS; Schultz N; Schrag D; Riely GJ;
Clin Cancer Res; 2023 Sep; 29(17):3418-3428. PubMed ID: 37223888
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
4. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
5. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
Liang YH; Chen KH; Shao YY
Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for appendiceal and colorectal peritoneal metastases.
Enblad M; Graf W; Birgisson H
Eur J Surg Oncol; 2018 Jul; 44(7):997-1005. PubMed ID: 29576463
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
Papamichael D; Lopes GS; Olswold CL; Douillard JY; Adams RA; Maughan TS; Van Cutsem E; Venook AP; Lenz HJ; Heinemann V; Kaplan R; Bokemeyer C; Chibaudel B; Grothey A; Yoshino T; Zalcberg J; De Gramont A; Shi Q
Eur J Cancer; 2022 Mar; 163():1-15. PubMed ID: 35033994
[TBL] [Abstract][Full Text] [Related]
10. A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer.
de Boer NL; Rovers K; Burger JWA; Madsen EVE; Brandt-Kerkhof ARM; Kok NFM; de Wilt JHW; de Reuver PH; Bos A; de Hingh IHJT; Verhoef C
Cancer Med; 2020 Aug; 9(16):5851-5859. PubMed ID: 32614506
[TBL] [Abstract][Full Text] [Related]
11. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery.
Peerenboom R; Dhiman A; Witmer HDD; Spurr LF; Polite B; Eng OS; Shergill A; Turaga KK
Ann Surg Oncol; 2023 May; 30(5):3114-3122. PubMed ID: 36637640
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
Marques RP; Godinho AR; Heudtlass P; Pais HL; Quintela A; Martins AP
J Cancer Res Clin Oncol; 2020 May; 146(5):1321-1334. PubMed ID: 32144533
[TBL] [Abstract][Full Text] [Related]
13. Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Meng L; Thapa R; Delgado MG; Gomez MF; Ji R; Knepper TC; Hubbard JM; Wang X; Permuth JB; Kim RD; Laber DA; Xie H
JAMA Netw Open; 2023 Jun; 6(6):e2320035. PubMed ID: 37358854
[TBL] [Abstract][Full Text] [Related]
14. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
[TBL] [Abstract][Full Text] [Related]
15. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
16. Genetic specificity study using next-generation sequencing (NGS) of peritoneal metastatic colorectal cancer compared to primary colorectal cancer.
Lee S; Shin W; Park DG; Namgung H
Genes Genomics; 2024 Mar; 46(3):289-302. PubMed ID: 38316717
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer.
Wang CY; Shao C; McDonald AC; Amonkar MM; Zhou W; Bortnichak EA; Liu X
JCO Clin Cancer Inform; 2023 Jul; 7():e2200184. PubMed ID: 37437227
[TBL] [Abstract][Full Text] [Related]
18. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
Sahin S; Karatas F
J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
[TBL] [Abstract][Full Text] [Related]
19. AACR Project GENIE Biopharma Collaborative Releases Colorectal Cancer Dataset.
Cancer Discov; 2023 Jan; 13(1):OF6. PubMed ID: 36355341
[TBL] [Abstract][Full Text] [Related]
20. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
